Afobazol is a selective non-benzodiazepine anxiolytic.
Acting on sigma-1 receptors in the nerve cells of the brain, Afobazol stabilizes GABA / benzodiazepine receptors and restores their sensitivity to endogenous mediators of inhibition. Afobazol also increases the bioenergetic potential of neurons and has a neuroprotective effect: it restores and protects nerve cells.
The effect of the drug is realized mainly in the form of a combination of anxiolytic (anti-anxiety) and mild stimulating (activating) effects. Afobazol reduces or eliminates feelings of anxiety (concern, bad feelings, fears), irritability, tension (fearfulness, tearfulness, anxiety, inability to relax, insomnia, fear), depressive mood, somatic manifestations of anxiety (muscle, sensory, cardiovascular, respiratory, gastrointestinal symptoms), autonomic disorders (dry mouth, sweating, dizziness), cognitive disorders (difficulty concentrating, impaired memory), incl. arising from stress disorders (adjustment disorders). The use of the drug is especially shown in persons with predominantly asthenic personality traits in the form of anxious suspiciousness, uncertainty, increased vulnerability and emotional lability, a tendency to emotional stress reactions.
The effect of the drug develops on the 5-7th day of treatment. The maximum effect is achieved by the end of 4 weeks of treatment and remains after the end of treatment for an average of 1-2 weeks.
Afobazol does not cause muscle weakness, drowsiness and does not have a negative effect on concentration and memory. When using it, addiction, drug dependence and “withdrawal” syndrome do not develop.
Application methods
It is applied orally, after meals.
The optimal single dose is 10 mg; daily allowance – 30 mg, divided into 3 doses during the day. The duration of the course is 2-4 weeks.
Reviews
There are no reviews yet.